BioCentury
ARTICLE | Company News

Avid Therapeutics deal

November 14, 1994 8:00 AM UTC

Avid (Philadelphia) received exclusive rights from Emory University to develop polyoxometalates to treat respiratory syncytial virus (RSV) and influenza. Avid said that although the compounds have a h...